Welcome to Mesothelioma.net - Turning Hope and Faith into Action.

Clinical Testing of Anti-Tumor Mesothelioma Drug Begins

A phase 1 trial of a new mesothelioma and ovarian cancer drug has begun at the National Cancer Institute at the National Institutes of Health and Washington University at St. Louis, and mesothelioma victims are hopeful that it will provide the same positive results in humans as it has shown in initial laboratory testing. The drug is known as MCY-M11, an autologous CAR drug candidate made by MaxCyte. Initial testing has shown that when infused into mesothelin-expressing solid tumors like those seen in both ovarian cancer and peritoneal mesothelioma, it will effectively inhibit the growth of the tumors, providing extended survival for those afflicted with these deadly diseases.

The drug, which is currently being tested on both ovarian cancer patients and patients diagnosed with peritoneal mesothelioma, had previously been evaluated in nonclinical studies. That research showed that a single injection of MCY-M11 led to inhibition of tumor growth as well as extended overall survival of laboratory animals, and that when the drug was injected weekly its impact was even greater – the more injections the animals received, the greater the effect. Importantly, the study revealed no toxicities outside of the tumors as a result of the injections.

While mesothelioma patients and their loved ones are watching the program with great anticipation, they also understand that it may take some time before the drug is available outside of the clinical trial. Though MaxCyte does participate in expanded access of its experimental drugs,   MCY-M11 is in its earliest stage of development and testing, and therefore patients are only able to gain access to it through the clinical trial process. Patients are invited to determine whether they are eligible to enroll through www.clinicaltrials.gov.

 

At Mesothelioma.net, we appreciate the sense of urgency that comes with a mesothelioma diagnosis, whether it is you that is sick or someone you love. For information about the many resources available to you, contact our Patient Advocates at 1-800-692-8608.

Terri Oppenheimer

Terri Oppenheimer is an experienced blog writer, editor, and proofreader. She graduated from the College of William and Mary with a degree in English. She specializes in providing content for websites and finds tremendous enjoyment in the things she learns while doing her research. Her specific areas of expertise include health, medical research, and law.

Get Your FREE Resources Sent Overnight

resources-shot_optimized
  • New treatment options
  • Veterans benefits & claims
  • $30 Billion asbestos trust fund information

– Or Call –
1-800-692-8608


Site Navigation

Where can I

Get Additional Help?

For over 20 years, we’ve provided the best FREE resources to mesothelioma patients and loved ones. Our resources include information on the leading treatment options and best doctors in your area; lessons learned from survivors; claims and benefits specifically for Veterans; and how to access your share of billions of dollars in trust fund money.

Get Your FREE Resources Sent Overnight

resources-shot_optimized
  • New Treatment Options
  • Veteran's Benefits & Claims
  • $30 Billion Asbestos Trust Fund Information

– Or Call –
1-800-692-8608

We are here to help you

support_staff

If you've been diagnosed with asbestos-related cancer, contact us at 1-800-692-8608 to find out if you are eligible to receive compensation. You can also fill out the form above to receive FREE information.

$30 Billion Asbestos Trusts
Get Started